- Preliminary clinical data on G1T28 in combination with chemotherapy in newly diagnosed small-cell lung cancer patients
- Preclinical data on potential best-in-class oral CDK4/6 inhibitor G1T38
RESEARCH TRIANGLE PARK, N.C., April 15, 2016 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc ., a clinical-stage oncology company, announced today that preliminary data from the Phase 1b/2a study of its lead CDK4/6 inhibitor G1T28 as a first-line combination treatment for small-cell lung cancer (SCLC) will be presented in a poster session at the 2016 American Association for Cancer Research (AACR) Annual Meeting, being held April 16 – 20 at the Ernest N. Morial Convention Center in New Orleans, La. In addition, G1 will present preclinical data on its CDK4/6 inhibitor G1T38 in two posters.
Details of the posters to be presented are as follows:
Title: G1T28, a cyclin dependent kinase 4/6 inhibitor, in combination with etoposide and carboplatin for extensive stage small cell lung cancer (ES-SCLC): preliminary results Abstract Number: CT151 Poster Session: Phase I Clinical Trials 2, Section 13 Date : Wednesday, April 20 Time : 8 a.m. - 12 p.m. CDT Presenter: Caio Max Rocha Lima, M.D.; Spartanburg Regional Healthcare System
Title: Effects of a CDK 4/6 inhibitor, G1T38, in androgen receptor sensitive and resistant models of castrate resistant prostate cancer Abstract Number: 2820 Poster Session: Pharmacological Inhibitors of Cyclin-dependent Kinases, Section 6 Date : Tuesday, April 19 Time : 8 a.m. - 12 p.m. CDT Presenter: Suzanne Wardell, Ph.D.; Assistant Professor, Duke University School of Medicine
Title: G1T38, a novel, oral, potent and selective CDK4/6 inhibitor for the treatment of Rb competent tumors Abstract Number: 2824 Poster Session: Pharmacological Inhibitors of Cyclin-dependent Kinases, Section 6 Date : Tuesday, April 19 Time : 8 a.m. - 12 p.m. CDT Presenter: Jay Strum, Ph.D.; Chief Scientific Officer, G1 Therapeutics
Abstracts for each poster and additional information on the meeting can be found on the AACR website: http://www.aacr.org/ .
About G1T28
G1T28 is a potential first-in-class combination therapy given intravenously prior to chemotherapy for the treatment of patients with CDK4/6-independent tumors. G1T28 induces a transient cell-cycle arrest of hematopoietic stem and progenitor cells, thereby protecting the bone marrow and immune system from damage by chemotherapy. G1T28 has the potential to significantly improve outcomes for patients with CDK4/6-independent tumors, such as small-cell lung cancer.
G1T28 is being studied in two Phase 1b/2a proof-of-concept trials in patients with small-cell lung cancer: a study in newly diagnosed, treatment-naive patients ( NCT02499770 ), and a study in previously treated patients ( NCT02514447 ).
About G1T38
G1T38 is an oral antineoplastic agent for the treatment of patients with CDK4/6-dependent tumors. In preclinical models, G1T38 enhances anti-tumor activity when combined with therapies that inhibit validated targets, such as the estrogen and androgen receptors. Due to its high selectivity and unique pharmacokinetic and pharmacodynamic profile, G1T38 has the potential to be best-in-class versus other CDK4/6 inhibitors in development.
G1 plans to initiate a Phase 1 clinical trial of G1T38 in the second quarter of 2016.
About G1 Therapeutics, Inc.
G1 Therapeutics is a clinical-stage oncology company developing novel, small-molecule therapies that address significant unmet needs in people with cancer. The company is advancing G1T28, a potential first-in-class drug candidate, and G1T38, a potential best-in-class compound, in multiple oncology indications. G1 is privately held and based in Research Triangle Park, NC.
Visit www.g1therapeutics.com for more information.
Contact: Mark Velleca, MD, PhD G1 Therapeutics 919-213-9838 mvelleca@g1therapeutics.com Media: Laura Bagby 6 Degrees Communications 312-448-8098 lbagby@6degreespr.com
